Skip to main content

Table 1 Baseline characteristics

From: Illustration of association between change in prostate-specific antigen (PSA) values and time to tumor status after treatment for prostate cancer patients: a joint modelling approach

 

Right Censored

(N = 544)

Low

(N = 960)

Overall

(N = 1504)

PSA

   

 Mean (SD)

40.5 (17.3)

29.3 (14.7)

33.4 (16.6)

 Median [Min, Max]

41.8 [3.35, 129]

30.1 [0.280, 89.7]

33.7 [0.280, 129]

BMI

   

 Mean (SD)

19.1 (2.27)

19.7 (2.04)

19.5 (2.14)

 Median [Min, Max]

19.2 [14.0, 26.5]

19.8 [14.1, 26.0]

19.6 [14.0, 26.5]

Treatment

   

 ADT

108 (19.9%)

220 (22.9%)

328 (21.8%)

 ADT + EBRT

168 (30.9%)

185 (19.3%)

353 (23.5%)

 ADT + Prostatectomy

49 (9.0%)

29 (3.0%)

78 (5.2%)

 ADT + Prostatectomy + EBRT

16 (2.9%)

11 (1.1%)

27 (1.8%)

 EBRT

101 (18.6%)

377 (39.3%)

478 (31.8%)

 Prostatectomy

83 (15.3%)

78 (8.1%)

161 (10.7%)

 Prostatectomy + EBRT

19 (3.5%)

60 (6.3%)

79 (5.3%)

Time

   

 Mean (SD)

224 (83.9)

250 (90.1)

241 (88.8)

 Median [Min, Max]

218 [64.0, 458]

248 [68.0, 486]

237 [64.0, 486]